{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:24:27Z","timestamp":1791051867842,"version":"4.1.0"},"reference-count":74,"publisher":"IMR Press","issue":"1","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Prostate cancer is the most frequent genitourinary tumor worldwide. Maintaining an optimum bone health throughout the natural course of prostate cancer is an important aspect in the management of this disease, particularly in this at risk population of older and frail patients who experience bone loss related to androgen-deprivation therapy (ADT) and\/or patients who develop bone metastases. The number of treatment options for advanced prostate cancer that combine ADT with docetaxel, new hormonal agents and\/or radiotherapy has increased substantially in recent years. Bisphosphonates and other bone targeted agents such as denosumab have shown an improvement in bone mineral density and are suited for patients with treatment-related osteoporosis and\/or bone metastases with an increased risk of skeletal-related events (SREs). In this context, the aim of this review is to analyse key aspects of bone health and therapies that can prevent the occurrence of SREs throughout the clinical course of prostate cancer, and how to combine them with new available treatments in this setting.<\/jats:p>","DOI":"10.31083\/j.fbl2701034","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T09:32:41Z","timestamp":1642757561000},"source":"Crossref","is-referenced-by-count":8,"title":["Bone health and therapeutic agents in advanced prostate cancer"],"prefix":"10.31083","volume":"27","author":[{"given":"Maria Antonia","family":"G\u00f3mez-Aparicio","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario de Toledo, 45007 Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"L\u00f3pez-Campos","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lira","family":"Pelari-Mici","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Buchser","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Cruces, 48903 Barakaldo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Pastor","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, ASCIRES Hospital General Universitario de Valencia, 46014 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Maldonado","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hospital Vall d\u00b4Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zafra","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Virgen de la Victoria, 29010 Malaga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison C.","family":"Tree","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Royal Marsden Hospital and Institute of Cancer Research, SM2 5PT Sutton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Bultijnck","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Ghent University Hospital, 9000 Ghent, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Institut Bergoni\u00e9, 33000 Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piet","family":"Ost","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Iridium Network, 2610 Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Cou\u00f1ago","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario Quironsalud, Hospital La Luz, Universidad Europea de Madrid, 28223 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary patterns of androgen deprivation therapy use for newly diagnosed prostate cancer. Urology. 2002; 60: 7\u201311.","DOI":"10.1016\/S0090-4295(02)01560-1"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, et al. Cancer Treatment\u2013Induced Bone Loss in Breast and Prostate Cancer. Journal of Clinical Oncology. 2008; 26: 5465\u20135476.","DOI":"10.1200\/JCO.2008.18.4184"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Al-Shamsi HO, Lau AN, Malik K, Alamri A, Ioannidis G, Corbett T, et al. The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer. Journal of Oncology. 2012; 2012: 1\u20137.","DOI":"10.1155\/2012\/958596"},{"key":"ref4","unstructured":"Rosino Sanchez A. Manejo preventivo de la enfermedad \u00f3sea en c\u00e1ncer de pr\u00f3stata avanzado. Archivos Espa\u00f1oles de Urolog\u00eda. 2018; 71, N: 258\u2013266. (In Spanish)"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Walsh PC. Risk of fracture after androgen deprivation for prostate cancer. The Journal of Urology. 2005; 174: 929\u2013930.","DOI":"10.1097\/S0022-5347(01)68451-9"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Shahinian VB, Kuo Y, Freeman JL, Goodwin JS. Risk of Fracture after Androgen Deprivation for Prostate Cancer. New England Journal of Medicine. 2005; 352: 154\u2013164.","DOI":"10.1056\/NEJMoa041943"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Oster G, Lamerato L, Glass AG, Richert-Boe KE, Lopez A, Chung K, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large us health systems. Supportive Care in Cancer. 2013; 21: 3279\u20133286.","DOI":"10.1007\/s00520-013-1887-3"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Smith MR, Saad F, Oudard S, Shore N, Fizazi K, Sieber P, et al. Denosumab and Bone Metastasis\u2013Free Survival in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time. Journal of Clinical Oncology. 2013; 31: 3800\u20133806.","DOI":"10.1200\/JCO.2012.44.6716"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Smith MR, Egerdie B, Toriz NH, Feldman R, Tammela TLJ, Saad F, et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine. 2009; 361: 745\u2013755.","DOI":"10.1056\/NEJMoa0809003"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011; 377: 813\u2013822.","DOI":"10.1016\/S0140-6736(10)62344-6"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Morote J, Planas J. P\u00e9rdida de masa \u00f3sea en pacientes con c\u00e1ncer de pr\u00f3stata sometidos a deprivaci\u00f3n androg\u00e9nica. Actas Urol\u00f3Gicas Espa\u00f1Olas. 2011; 35: 232\u2013239. (In Spanish)","DOI":"10.1016\/j.acuro.2011.01.008"},{"key":"ref12","unstructured":"Brawer MK. Hormonal therapy for prostate cancer. Reviews in Urology. 2006; 8: S35\u2013S47."},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, et al. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007; 69: 500\u2013504.","DOI":"10.1016\/j.urology.2006.11.002"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology. 2020; 77: 508\u2013547.","DOI":"10.1016\/j.eururo.2020.01.012"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Suominen MI, Fagerlund KM, Rissanen JP, Konkol YM, Morko JP, Peng Z, et al. Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models. Clinical Cancer Research. 2017; 23: 4335\u20134346.","DOI":"10.1158\/1078-0432.CCR-16-2955"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Auchus RJ, Yu MK, Nguyen S, Mundle SD. Use of Prednisone with Abiraterone Acetate in Metastatic Castration\u2010Resistant Prostate Cancer. The Oncologist. 2014; 19: 1231\u20131240.","DOI":"10.1634\/theoncologist.2014-0167"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology. 2019; 20: 408\u2013419.","DOI":"10.1016\/S1470-2045(18)30860-X"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, et al. Impact of Bone-targeted Therapies in Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. European Urology. 2015; 68: 570\u2013577.","DOI":"10.1016\/j.eururo.2015.04.032"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016; 387: 1163\u20131177.","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. The Lancet Oncology. 2014; 15: 738\u2013746.","DOI":"10.1016\/S1470-2045(14)70183-4"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, et al. Predictive value of BMD for hip and other fractures. Journal of Bone and Mineral Research. 2005; 20: 1185\u20131194.","DOI":"10.1359\/JBMR.050304"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster J-Y. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International. 2019; 30: 3\u201344.","DOI":"10.1007\/s00198-018-4704-5"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women. Journal of the American Medical Association. 2001; 286: 2815.","DOI":"10.1001\/jama.286.22.2815"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017; 12: 43.","DOI":"10.1007\/s11657-017-0324-5"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"McCloskey EV, Harvey NC, Johansson H, Kanis JA. FRAX updates 2016. Current Opinion in Rheumatology. 2016; 28: 433\u2013441.","DOI":"10.1097\/BOR.0000000000000304"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Briot K, Paccou J, Beuzeboc P, Bonneterre J, Bouvard B, Confavreux CB, et al. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation. Joint Bone Spine. 2019; 86: 21\u201328.","DOI":"10.1016\/j.jbspin.2018.09.017"},{"key":"ref27","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2021. ISBN 978-94-92671-13-4."},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Coleman R, Hadji P, Body J-J, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2020; 31: 1650\u20131663.","DOI":"10.1016\/j.annonc.2020.07.019"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Hadji P, Aapro MS, Body J-J, Gnant M, Brandi ML, Reginster JY, et al. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG. Journal of Bone Oncology. 2017; 7: 1\u201312.","DOI":"10.1016\/j.jbo.2017.03.001"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Saylor PJ, Kaufman DS, Michaelson MD, Lee RJ, Smith MR. Application of a Fracture Risk Algorithm to Men Treated with Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology. 2010; 183: 2200\u20132205.","DOI":"10.1016\/j.juro.2010.02.022"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Bressi B, Cagliari M, Contesini M, Mazzini E, Bergamaschi FAM, Moscato A, et al. Physical exercise for bone health in men with prostate cancer receiving androgen deprivation therapy: a systematic review. Supportive Care in Cancer. 2021; 29: 1811\u20131824.","DOI":"10.1007\/s00520-020-05830-1"},{"key":"ref32","unstructured":"Network NCC. No Title [Internet]. Prostate cancer Version 1.2022. 2022. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (Accessed: 15 December 2021)."},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Reyes-Garc\u00eda R, Garc\u00eda-Mart\u00edn A, Varsavsky M, Rozas-Moreno P, Cort\u00e9s-Berdonces M, Luque-Fern\u00e1ndez I, et al. Actualizaci\u00f3n de las recomendaciones para la evaluaci\u00f3n y tratamiento de la osteoporosis asociada a enfermedades endocrinas y nutricionales. Grupo de trabajo de osteoporosis y metabolismo mineral de la SEEN. Endocrinolog\u00eda Y Nutrici\u00f3N. 2015; 62: e47\u2013e56. (In Spanish)","DOI":"10.1016\/j.endonu.2015.01.011"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Alibhai SMH, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, et al. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D. Osteoporosis International. 2013; 24: 2571\u20132579.","DOI":"10.1007\/s00198-013-2343-4"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Formenti AM, Dalla Volta A, di Filippo L, Berruti A, Giustina A. Effects of Medical Treatment of Prostate Cancer on Bone Health. Trends in Endocrinology & Metabolism. 2021; 32: 135\u2013158.","DOI":"10.1016\/j.tem.2020.12.004"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Jakob T, Tesfamariam YM, Macherey S, Kuhr K, Adams A, Monsef I, et al. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. Cochrane Database of Systematic Reviews. 2020; 12: CD013020.","DOI":"10.1002\/14651858.CD013020.pub2"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. Journal of Urology. 2003; 169: 2008\u20132012.","DOI":"10.1097\/01.ju.0000063820.94994.95"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic Acid Initiated During the First Year of Androgen Deprivation Therapy Increases Bone Mineral Density in Patients With Prostate Cancer. Journal of Urology. 2006; 176: 972\u2013978.","DOI":"10.1016\/j.juro.2006.04.078"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, et al. Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist\u2013Induced Bone Loss in Men with Prostate Cancer. Journal of Clinical Oncology. 2007; 25: 1038\u20131042.","DOI":"10.1200\/JCO.2006.07.3361"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, et al. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. Prostate Cancer and Prostatic Diseases. 2013; 16: 382\u2013386.","DOI":"10.1038\/pcan.2013.35"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine. 2018; 378: 2465\u20132474.","DOI":"10.1056\/NEJMoa1800536"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. New England Journal of Medicine. 2018; 378: 1408\u20131418.","DOI":"10.1056\/NEJMoa1715546"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine. 2019; 380: 1235\u20131246.","DOI":"10.1056\/NEJMoa1815671"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012; 37: 39\u201346.","DOI":"10.1016\/S0140-6736(11)61226-9"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Wirth M, Tammela T, Cicalese V, Gomez Veiga F, Delaere K, Miller K, et al. Prevention of Bone Metastases in Patients with High-risk Nonmetastatic Prostate Cancer Treated with Zoledronic Acid: Efficacy and Safety Results of the Zometa European Study (ZEUS). European Urology. 2015; 67: 482\u2013491.","DOI":"10.1016\/j.eururo.2014.02.014"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients with Hormone-Refractory Metastatic Prostate Carcinoma. JNCI Journal of the National Cancer Institute. 2002; 94: 1458\u20131468.","DOI":"10.1093\/jnci\/94.19.1458"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Metastatic Hormone-Refractory Prostate Cancer. JNCI Journal of the National Cancer Institute. 2004; 96: 879\u2013882.","DOI":"10.1093\/jnci\/djh141"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Barghout V, Abetz L, Arbuckle R, Bosch V, Hei Y, Saad F. Effect of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases based on performance status. Journal of Clinical Oncology. 2006; 24: 14544.","DOI":"10.1200\/jco.2006.24.18_suppl.14544"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Abetz L, Barghout V, Arbuckle R, Bosch V, Shirina N, Saad F. Impact of zoledronic acid (Z) on pain in prostate cancer patients with bone metastases in a randomised placebo-control trial. Journal of Clinical Oncology. 2006; 24: 4638\u20134638.","DOI":"10.1200\/jco.2006.24.18_suppl.4638"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Saad F, Eastham J. Zoledronic Acid Improves Clinical Outcomes when Administered before Onset of Bone Pain in Patients with Prostate Cancer. Urology. 2010; 76: 1175\u20131181.","DOI":"10.1016\/j.urology.2010.05.026"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Saad F. New research findings on zoledronic acid: Survival, pain, and anti-tumour effects. Cancer Treatment Reviews. 2008; 34: 183\u2013192.","DOI":"10.1016\/j.ctrv.2007.10.002"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Pan Y, Jin H, Chen W, Yu Z, Ye T, Zheng Y, et al. Docetaxel with or without zoledronic acid for castration-resistant prostate cancer. International Urology and Nephrology. 2014; 46: 2319\u20132326.","DOI":"10.1007\/s11255-014-0824-9"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"James ND, Pirrie SJ, Pope AM, Barton D, Andronis L, Goranitis I, et al. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer with Docetaxel alone or with Strontium-89, Zoledronic Acid, or both. JAMA Oncology. 2016; 2: 493.","DOI":"10.1001\/jamaoncol.2015.5570"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. 2012; 48: 3082\u20133092.","DOI":"10.1016\/j.ejca.2012.08.002"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Annals of Oncology. 2015; 26: 368\u2013374.","DOI":"10.1093\/annonc\/mdu519"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Clemons M, Liu M, Stober C, Pond G, Jemaan Alzahrani M, Ong M, et al. Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer. Journal of Bone Oncology. 2021; 30: 100388.","DOI":"10.1016\/j.jbo.2021.100388"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Gillessen S, Choudhury A, Rodriguez-Vida A, Nole F, Gallardo Diaz E, Roumeguere TA, et al. Decreased fracture rate by mandating bone protecting agents in the EORTC 1333\/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: an updated safety analysis. Journal of Clinical Oncology. 2021; 39: 5002\u20135002.","DOI":"10.1200\/JCO.2021.39.15_suppl.5002"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"O\u2019Sullivan JM, Carles J, Cathomas R, Gomez-Iturriaga A, Heinrich D, Kramer G, et al. Radium-223 within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. European Urology Oncology. 2020; 3: 455\u2013463.","DOI":"10.1016\/j.euo.2019.02.007"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O\u2019Sullivan JM, Foss\u00e5 SD, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. New England Journal of Medicine. 2013; 369: 213\u2013223.","DOI":"10.1056\/NEJMoa1213755"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Saylor PJ, Rumble RB, Tagawa S, Eastham JA, Finelli A, Reddy PS, et al. Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. Journal of Clinical Oncology. 2020; 3: 1736\u20131743.","DOI":"10.1200\/JCO.19.03148"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. The New England Journal of Medicine. 2014; 371: 424\u2013433.","DOI":"10.1056\/NEJMoa1405095"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, et al. Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). Journal of Clinical Oncology. 2014; 32: 1143\u20131150.","DOI":"10.1200\/JCO.2013.51.6500"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Kamba T, Kamoto T, Maruo S, Kikuchi T, Shimizu Y, Namiki S, et al. A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. International Journal of Clinical Oncology. 2017; 22: 166\u2013173.","DOI":"10.1007\/s10147-016-1037-2"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. The New England Journal of Medicine. 2017; 377: 352\u2013360.","DOI":"10.1056\/NEJMoa1704174"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. New England Journal of Medicine. 2017; 377: 338\u2013351.","DOI":"10.1056\/NEJMoa1702900"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard first-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine. 2019; 381: 121\u2013131.","DOI":"10.1056\/NEJMoa1903835"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, Gomes AJP de S, Given R, et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. New England Journal of Medicine. 2019; 202: 661.","DOI":"10.1056\/NEJMoa1903307"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a Randomized, Phase III Study of Androgen Deprivation Therapy with Enzalutamide or Placebo in Men with Metastatic Hormone-Sensitive Prostate Cancer. Journal of Clinical Oncology. 2019; 37: 2974\u20132986.","DOI":"10.1200\/JCO.19.00799"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Liu C, Wang L, Liu L, Zhuang J, Tang S, Zhang T, et al. Efficacy and safety of de-escalation bone-modifying agents for cancer patients with bone metastases: a systematic review and meta-analysis. Cancer Management and Research. 2018; 10: 3809\u20133823.","DOI":"10.2147\/CMAR.S176811"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Templeton AJ, Stalder L, Albiges Sauvin L, Bernhard J, Brauchli P, Gillessen S, et al. Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks Versus every 12 Weeks\u2013a Non-Inferiority Phase III Trial: Sakk 96\/12 - Reduse. Annals of Oncology. 2014; 25: iv540.","DOI":"10.1093\/annonc\/mdu356.71"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Clemons M, Ong M, Stober C, Ernst S, Booth C, Canil C, et al. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. European Journal of Cancer. 2021; 142: 132\u2013140.","DOI":"10.1016\/j.ejca.2020.08.019"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Fizazi K, Higano CS, Nelson JB, Gleave M, Miller K, Morris T, et al. Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination with Zibotentan in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 2013; 31: 1740\u20131747.","DOI":"10.1200\/JCO.2012.46.4149"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. The Lancet Oncology. 2013; 14: 1307\u20131316.","DOI":"10.1016\/S1470-2045(13)70479-0"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, et al. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. Journal of Clinical Oncology. 2016; 34: 3005\u20133013.","DOI":"10.1200\/JCO.2015.65.5597"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/1\/10.31083\/j.fbl2701034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:42:56Z","timestamp":1732707776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/1\/10.31083\/j.fbl2701034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2768-6701(22)00372-0"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2701034","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"article-number":"34"}}